Diabemac Members Links Publications
Diabemac

The research team "Nuclear Receptor Signaling" led by Dr. Mercedes Ricote was established as a research group at the National Center for Cardiovascular Research (CNIC) in 2004. Recently, they have relocated their laboratory to the National Center for Biotechnology (CNB-CSIC), where Dr. Ricote is a researcher at the CSIC. The research team of Dr. Mercedes Ricote is composed of members with extensive experience in the study of macrophages and nuclear receptors in the context of chronic inflammatory diseases such as diabetes and atherosclerosis. The principal investigator has been working for over 20 years in the field of nuclear receptor signaling in metabolic and cardiovascular diseases and has obtained public funding (SAF2017-90604-REDT, RTI2018-095928-B-I00, PID2021-12255OB-B-I00), regional funding (B2017/BMD-3684, P2022/BMD-7227), private funding (Mutua Madrileña Foundation, La Marató TV3), and European funding (FP7-PEOPLE-2005-IRG, FP7-PEOPLE-2008-IEF, FP7-PEOPLE-2009-RG, EFSD/Lilly Research Fellowships, FP7-PEOPLE-2013-ITN) to conduct studies focused on elucidating the molecular mechanisms regulating macrophage activation and differentiation processes in homeostasis and in metabolic and cardiovascular diseases. Additionally, they have recently initiated a new line of research examining signal transmission between mothers and neonates and its impact on energy homeostasis control. To carry out these projects, the research group has established a wide range of state-of-the-art technologies such as omics (RNAseq, ChIPseq, and ATACseq), animal models, conditional knockout mice, and advanced non-invasive imaging techniques.

Additionally, Dr. Mercedes Ricote has supervised 7 doctoral theses and has overseen numerous master's projects and internships for vocational training students. Dr. Mercedes Ricote is invited to national and international congresses as a speaker and moderator at the level of "Keystone Symposium," "EMBO," FEBS..., indicating that she is a researcher of recognized prestige in the field of nuclear receptors. The research group has international collaborations with Drs. C. Glass (UCSD, La Jolla, USA), J. Cancelas (Cincinnati Children's Hospital, USA), D. Metzger (IGBMC, France), E. Treuter (Karolinksa Institute, Stockholm, Sweden); as well as national collaborations with groups belonging to MOIR2: Drs. G. Medina (URJC, Madrid) and M.P. Ramos (CEU, Madrid).



Financing for the last 5 years:

  • [2023-2026]. COMMUNITY OF MADRID. Advancing in the knowledge of new markers, mechanisms, and tissue interactome in situations of insulin resistance. (P2022/BMD-7227). PI: Dr. M. Ricote.

  • [2022-2025]. MINISTRY OF SCIENCE, INNOVATION AND UNIVERSITIES. Transcriptional and epigenetic control of the development of tissue-resident macrophages by nuclear receptors: role of the niche. (PID2021-12255OB-B-I00). PI: Dr. M. Ricote.

  • [2019-2021]. MINISTRY OF SCIENCE, INNOVATION AND UNIVERSITIES. Role of the RXR nuclear receptor in the origin, differentiation, and functions of tissue macrophages. (RTI2018-095928-B-100). IP: Dr. M. Ricote.

  • [2018-2020]. MINISTRY OF ECONOMY AND COMPETITIVENESS. Thematic network of nuclear receptors in cancer, metabolism, and inflammation. (SAF2017-90604-REDT). IP: Dr. M. Ricote. Coordinator: Dr. M. Ricote.

  • [2018-2021]. COMMUNITY OF MADRID. Molecular Mechanisms and Intertissue Communication in Insulin Resistance. (B2017/BMD-3684). IP: Dr. M. Ricote. Coordinator: Dr. G. Medina.

  • [2017-2019]. TV3 MARATÓ FOUNDATION. Systemic and tissue-specific control by nuclear receptors of obesity-induced insulin resistance. (ref. 201605-32). IP: Dr. M. Ricote. Coordinator: Dr. C. Caelles Franch.